Unlike Alzheimer's disease (AD), which took much of the spotlight Friday, "there's not another gene to argue over" in Parkinson's disease (PD), said CEO Dale Schenk, commenting on Prothena Corp. plc's phase I success with PRX002, which takes aim at alpha-synuclein.